AZ ST-JAN Brugge A.V.

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Bladder cancer4 trials
• Diffuse large B-cell lymphoma2 trials
• Multiple sclerosis2 trials
• Narcolepsy2 trials
• Atrial fibrillation1 trial
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Endometriosis1 trial
• Graves' disease1 trial
• Lung cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 310 trials
• Phase 24 trials
• Phase 42 trials

Status

• Recruiting8 trials
• Active, not recruiting5 trials
• Not yet recruiting2 trials
• Withdrawn1 trial

Lead sponsor

• Janssen Research & Development, LLC4 trials
• Alkermes Inc.2 trials
• Amgen Inc.1 trial
• BioNTech SE1 trial
• Boehringer Ingelheim1 trial
• and 7 more

Running trials

• Recruiting

  ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole

  2025-524995-53-00· Phase 4· UZ Brussel· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation

  NCT07405671· Phase 4· Universitaire Ziekenhuizen KU Leuven· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

  2025-523912-35-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

  2025-523911-13-00· Phase 3· Alkermes Inc.· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· BioNTech SE· Source

• Active, not recruiting

  Non-inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis.

  2024-519304-28-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· Phase 2· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Narcolepsy2 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometriosis1 recruiting
• Graves' disease1 recruiting
• Lung cancer1 recruiting
• Multiple sclerosis1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Not yet recruiting

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source